Ocuphire Pharma has announced the acquisition of Opus Genetics to create a biotech company dedicated to gene therapy ...

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...

On Wednesday, Ocuphire Pharma, Inc. (NASDAQ:OCUP) announced the all-stock acquisition of Opus Genetics, Inc., a ...

Canaccord lowered the firm’s price target on Ocuphire Pharma (OCUP) to $10 from $18 and keeps a Buy rating on the shares. The firm noted ...

H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter. Published first on TheFly – the ultimate source for ...

The company will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for ...

The eye drop maker Ocuphire Pharma and startup Opus Genetics are merging in an all-stock deal, the companies told Endpoints ...

In the transaction, Ocuphire will issue 5.2 million shares of its common stock and 14.1 thousand shares of its convertible preferred stock to existing stockholders of Opus Genetics. Ocuphire insiders ...

Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies ...

Traders use this information to analyze potential trades and assess market sentiment for Ocuphire Pharma. In The Money Expiration Date October 18, 2024 November 15, 2024 December 20, 2024 February ...

FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing ...